Lipocine Positive Week 52 Results from LPCN 1148 Phase 2 Study in Cirrhosis

 

• Met primary and Hepatic Encephalopathy (HE) endpoints in Phase 2 study
  • Increase in Skeletal Muscle Index (SMI) observed at Week 24 was maintained through 52 weeks
  • Participants on placebo increased SMI when switched to LPCN 1148
  • Fewer Overt Hepatic Encephalopathy (OHE) events and time to first recurrent OHE event was longer while on LPCN 1148 therapy
• LPCN 1148 was well-tolerated, with AE rates and severities similar to placebo.
• Participants on LPCN 1148 were hospitalized for fewer days

https://www.prnewswire.com/news-releases/lipocine-announces-positive-week-52-results-from-lpcn-1148-phase-2-study-in-patients-with-cirrhosis-302101966.html